ANTI-INSOMNIA COMPOSITIONS AND METHODS
Compositions of zolpidem, and methods for their manufacture and use for treating insomnia. The compositions are formulated as oral sprays for transmucosal absorption of zolpidem. The methods of treatment in some cases involve night-time dosing administration to achieve therapeutic zolpidem blood levels within 20 minutes or less, tapering off to less than 20 ng/ml within less than five hours, in some cases less than four hours, post dosing.
1 . A method for treatment of insomnia, comprising:
administering via oral spray to a patient suffering from insomnia a unit dose volume of about 50 to about 400 mcL of a pharmaceutical oral spray composition;
said unit dose volume containing between about 0.5 mg and about 5.0 mg of zolpidem or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable solvent for transmucosal absorption of a therapeutically effective amount of zolpidem to the patient's systemic circulatory system through the oral mucosa;
said administering being conducted in less than about five hours before the patient needs to resume wakeful activities and achieving a therapeutic zolpidem blood level within 23 minutes and tapering off to less than 20 ng/ml in less than five hours after administering the oral spray composition to said patient.
2 . The method of claim 1 , wherein the unit dose volume comprises between about 2.0 to 3.0 mg of zolpidem or a pharmaceutically acceptable salt thereof.
3 . The method of claim 1 , wherein the unit dose volume comprises about 2.5 mg of zolpidem or a pharmaceutically acceptable salt thereof.
4 . The method of claim 1 , wherein said administering is conducted in less than about four hours before the patient needs to resume wakeful activities.
5 . The method of claim 1 , wherein the composition comprises:
about 1.0 to about 10.0 weight percent zolpidem or a pharmaceutically acceptable salt thereof;
about 40 to about 60 percent water; and about 20 to 50 percent solvent.
6 . The method of claim 1 , wherein the composition comprises:
about 3.0 to about 7.0 weight percent zolpidem or a pharmaceutically acceptable salt thereof;
about 45 to about 50 percent water;
about 30 to 40 percent solvent.
7 . The method of claim 1 , wherein a therapeutic zolpidem blood level is achieved in less than 20 minutes, and tapers off to less than about 20 ng/ml in less than four hours, post dosing.
8 . A method for inducing sleep, comprising:
administering a dose of an oral spray composition to a patient suffering from insomnia;
said composition containing a sedative or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable solvent;
said administering being conducted within less than about five hours before the patient needs to arise from sleep.
9 . The method of claim 8 , wherein the sedative is zolpidem tartrate.
10 . The method of claim 8 , wherein the dose comprises about 0.5 to about 5.0 mg of zolpidem or a pharmaceutically acceptable salt thereof.
11 . The method of claim 8 , wherein the dose has a volume in the range from about 50 to about 400 mcL.
12 . The method of claim 8 , wherein the dose has a volume in the range from about 50 to about 200 mcL.
13 . The method of claim 8 , wherein a therapeutic zolpidem level is achieved within less than 30 minutes post dosing.
14 . The method of claim 8 , wherein a therapeutic zolpidem level is achieved within 23 minutes post dosing.
15 . The method of claim 8 , wherein a therapeutic zolpidem level is achieved within 22 minutes post dosing.
16 . The method of claim 8 , wherein a therapeutic zolpidem level is achieved within 13 minutes post dosing.
17 . The method of claim 8 , wherein a therapeutic zolpidem level is achieved within 12 minutes post dosing.
18 . The method of claim 11 , wherein zolpidem blood levels taper off to less than 20 ng/ml in less than five hours post dosing.
19 . The method of claim 11 , wherein zolpidem blood levels taper off to less than 20 ng/ml in less than four hours post dosing.
20 . The method according to claim 8 , wherein the solvent comprises a polar solvent selected from the group comprising water, acidified water, and aqueous buffers.
21 . The method according to claim 8 , wherein the solvent comprises a non-polar solvent selected from the group comprising propylene glycol and ethanol.
22 . The method according to claim 8 , wherein the composition further comprises a taste mask or flavoring agent.
23 . The method according to claim 8 , wherein the composition further comprises a propellant.
24 . A pharmaceutical anti-insomnia composition comprising:
zolpidem or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable solvent;
wherein said composition is contained in a unit dose spray pump container;
and wherein a single actuation of said container delivers a unit dose volume about 50 to about 400 mcL of said composition containing a dose of about 0.5 to 5 mg zolpidem or a pharmaceutically acceptable salt thereof.
25 . The composition of claim 24 , wherein the unit dose volume is about 50 to about 200 mcL.
26 . The composition of claim 24 , wherein the dose of zolpidem is about 2 to 3 mg.
27 . The composition of claim 24 , wherein upon delivery of the unit dose to a human patient by oral spray a therapeutic zolpidem level is achieved within less than 30 minutes post dosing.
28 . The composition of claim 24 , wherein upon delivery of the unit dose to a human patient by oral spray a therapeutic zolpidem level is achieved within 23 minutes post dosing.
29 . The composition of claim 24 , wherein upon delivery of the unit dose to a human patient by oral spray a therapeutic zolpidem level is achieved within 22 minutes post dosing.
30 . The composition of claim 24 , wherein upon delivery of the unit dose to a human patient by oral spray a therapeutic zolpidem level is achieved within 13 minutes post dosing.
31 . The composition of claim 24 , wherein upon delivery of the unit dose to a human patient by oral spray a therapeutic zolpidem level is achieved within 12 minutes post dosing.
32 . The composition of claim 24 , wherein upon delivery of the unit dose to a human patient by oral spray zolpidem blood levels taper off to less than 20 ng/ml in less than five hours post dosing.
33 . The composition of claim 24 , wherein upon delivery of the unit dose to a human patient by oral spray zolpidem blood levels taper off to less than 20 ng/ml in less than four hours post dosing.